Biosimilars LatAm – Colombia 2025
Focused on fostering greater access to biosimilars in Colombia, this forum gathers decision-makers from the pharmaceutical industry, regulatory bodies, and associations to share success stories and actionable insights. With dynamic presentations, interactive panels, and networking opportunities, the event emphasizes the strategic importance of vaccines and plasma-derived products. Discussions will cover recent regulatory advancements, strategies for self-sufficiency, and collaborations with leading institutions to build local biotech capabilities.
Key Objectives:
– Analyze recent regulatory and strategic advancements positioning Colombia on the biosimilars map, identifying areas for investment and alliances.
– Examine the role of the industry in ensuring self-sufficiency in critical medicines, exploring government incentives and integration policies.
– Investigate training programs in advanced skills and technology transfer through partnerships with leading Latin American institutions.
Who will
you meet?
More than:
Participants
Companies
HCPs
Patients
Academy
Investors
Institutions
Associations
Service Providers
Government Agencies
Industry Executives from Latam
- Biosimilars
- Biobetters
- Biotechnology
- Biotherapeutics
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Pharmacovigilance
- Research
- Regulatory
- Business Development
- Marketing
Speaker Board
Rocio Parra
Global Strategy Director
Sol Ruiz
Head of Biologics, Advanced Therapies, and Biotechnology
Tonatiuh Cortes Esquivel
Technology Transfer and Optimization Manager
Adriana Robayo
Executive Director
Claudia Vaca
Founder and Head
Program at a Glance
Advanced Local Regulation: Unlocking the Potential of Biosimilars
Discuss specific changes to the Colombian regulatory framework, with a focus on optimizing approval times and aligning with global standards.
Next Stage: Strategies for the Consolidation of the Colombian Biosimilar Industry
To review actionable strategies that could strengthen and position the Colombian biosimilar industry for sustainable growth and regional leadership.
Data Box: Results of Integration of AI and Machine Learning in Bioprocesses
To present how artificial intelligence and machine learning are transforming biosimilar production, increasing predictability and efficiency in manufacturing.
Capitalization Strategies for Expansion of the Biosimilar Sector
Detail complex financial models and capital investment strategies for the development of infrastructure and manufacturing of biosimilars in Colombia.
Redefining the Role of Industry in Colombian Health Autonomy
To delve deeper into the role of the industry in Colombia in ensuring self-sufficiency in critical medicines and to analyze government incentives and integration policies in the sector.
PDPs as a Catalyst for Innovation and Production of Biosimilars in Colombia
Explore Productive Development Programs (PDPs) and their implementation as a vehicle to attract investments in the biosimilars sector, inspired by the experience of Brazil.
Strengthening Capacities: Education and Technology Transfer
Analyze training programs in advanced competencies and alliances for technology transfer among leading institutions in Latin America.
Strategic Advances in the Colombian Biosimilars Market
To analyze recent strategic and regulatory steps that have positioned Colombia on the biosimilars map, highlighting areas of future investment and critical alliances.
Full Programme in the PDF Agenda
Download Agenda
Sponsors
Media Partners
Photo Gallery from Previous Events
Testimonials
-
”It was an excellent opportunity to hear what the authorities industry, even sometimes what our competitors or other providers have to say about the topic.”
Alison Bascou, Sr. Regulatory Director at BD, France
-
"I think it's being an interesting event. Wherever there's discussion at top level, wherever there's respect. wherever there's an open forum, science can advance. It's very important to keep patient's well-being in mind and I think this forum allows that."
Jaime Uribe, CEO At PROBIOMED
-
“The strength of the biosimilar industry in our region is very encouraging. It seems to me this event is the propitious forum to share experiences and it is great.”
Tammy Boggiano Ayo, Process Development Director at CIM, Cuba
-
“It showed a broad picture, from a highly technical perspective up to a commercial viewpoint. It is not easy to get that in such a short period of time.”
Santiago Salguero, Executive Director at Pharmaceutical Association of Ecuador
-
“For companies like those I work for, i.e. suppliers to the pharmaceutical industry, this has been a great opportunity to see our clients’ perspective and above all to identify the major trends determining the future of biosimilars.”
Mauricio Roberto Hernández Morales, Key Account and Business Developer Manager at BD Mexico